Is there justification for 4 cycles of consolidation therapy in AML?

Dohner, 2015, Acute myeloid leukemia, N Engl J Med, 373, 1136, 10.1056/NEJMra1406184 Papaemmanuil, 2016, N Engl J Med., 374, 2209, 10.1056/NEJMoa1516192 Ivey, 2016, Assessment of minimal residual disease in standard-risk AML, N Engl J Med, 374, 422, 10.1056/NEJMoa1507471 Cassileth, 1988, Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia, J Clin Oncol, 6, 583, 10.1200/JCO.1988.6.4.583 Mayer, 1994, Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B, N Engl J Med, 331, 896, 10.1056/NEJM199410063311402 Byrd, 1999, Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered, J Clin Oncol, 17, 3767, 10.1200/JCO.1999.17.12.3767 Farag, 2005, Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study, J Clin Oncol, 23, 482, 10.1200/JCO.2005.06.090 Burnett, 2013, Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial, J Clin Oncol, 31, 3360, 10.1200/JCO.2012.47.4874 Schlenk, 2013, Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia, Hematol Am Soc Hematol Educ Program, 2013, 324, 10.1182/asheducation-2013.1.324 Schlenk, 2016, All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study, Ann Hematol., 10.1007/s00277-016-2810-z